Skip to Content
Merck
  • Topoisomerase II SUMOylation activates a metaphase checkpoint via Haspin and Aurora B kinases.

Topoisomerase II SUMOylation activates a metaphase checkpoint via Haspin and Aurora B kinases.

The Journal of cell biology (2019-11-13)
Nootan Pandey, Daniel Keifenheim, Makoto Michael Yoshida, Victoria A Hassebroek, Caitlin Soroka, Yoshiaki Azuma, Duncan J Clarke
ABSTRACT

Topoisomerase II (Topo II) is essential for mitosis since it resolves sister chromatid catenations. Topo II dysfunction promotes aneuploidy and drives cancer. To protect from aneuploidy, cells possess mechanisms to delay anaphase onset when Topo II is perturbed, providing additional time for decatenation. Molecular insight into this checkpoint is lacking. Here we present evidence that catalytic inhibition of Topo II, which activates the checkpoint, leads to SUMOylation of the Topo II C-terminal domain (CTD). This modification triggers mobilization of Aurora B kinase from inner centromeres to kinetochore proximal centromeres and the core of chromosome arms. Aurora B recruitment accompanies histone H3 threonine-3 phosphorylation and requires Haspin kinase. Strikingly, activation of the checkpoint depends both on Haspin and Aurora B. Moreover, mutation of the conserved CTD SUMOylation sites perturbs Aurora B recruitment and checkpoint activation. The data indicate that SUMOylated Topo II recruits Aurora B to ectopic sites, constituting the molecular trigger of the metaphase checkpoint when Topo II is catalytically inhibited.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Thrombin from bovine plasma, lyophilized powder, ≥2,000 NIH units/mg protein (E1%/280 = 19.5)
Sigma-Aldrich
Anti-INCENP antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
L-α-Lysophosphatidylcholine from egg yolk, ≥99%, Type I, powder